Morepen Laboratories Approves FY Results, Recommends Dividend, and Finalizes Business Transfer Agreement
Morepen Laboratories Limited announced key outcomes from its Board of Directors meeting held on May 26, 2026. The Board approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, and recommended a final dividend of Rs. 0.20/- per equity share.The company also approved the Second Addendum to the Business Transfer Agreement (BTA) entered into with Morepen Medipath Limited, a subsidiary of the company. Furthermore, the Board re-appointed M/s. Vijender Sharma & Co. as the Cost Auditors for the financial year ending March 31, 2027.
Financial Performance and Dividend Recommendation
The Board of Directors recommended a final dividend of Rs. 0.20/- per equity share, which is based on the financial year ended March 31, 2026. This dividend is subject to the approval of the members at the ensuing Annual General Meeting.The company approved the audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026. The consolidated financial data provided key figures:
| Financial Metric | Quarterly Results (Rs. in Lakhs) | Full Year Results (Rs. in Lakhs) |
|---|---|---|
| Total Income | 49,317.96 | 182,700.56 |
| Total Expenditure | 46,989.21 | 173,291.10 |
| Net Profit after Minority Interest | 1,574.46 | 9,487.68 |
| Total Comprehensive Income | 636.31 | 618.91 |
Note: Financial figures are in Indian Rupees (Rs. in Lakhs), except for the dividend per share data.
Business Transfer Agreement Updates
The Board approved the Second Addendum to the Business Transfer Agreement, initially dated March 18, 2025, and previously amended on May 12, 2025. This addendum further revised the ‘Appointed Date’ for the transfer of the Medical Devices Business undertaking.Key details of the transaction include:
- Parties: Morepen Laboratories Limited and Morepen Medipath Limited (formerly Morepen Medtech Limited).
- Transaction: The transfer of the Medical Devices Business undertaking on a ‘slump sale’ basis.
- Revised Appointed Date: The second addendum sets the revised 'Appointed Date' as April 1, 2026.
- Stakeholding: Morepen Laboratories Limited holds a 51% paid-up equity share capital of Morepen Medipath Limited.
Governance and Audit Appointments
Regarding corporate governance, the Board re-appointed M/s. Vijender Sharma & Co., a partnership firm of practicing Cost Accountants, as the Cost Auditors. This reappointment is effective for the financial year ended March 31, 2027.Comprehensive Financial Summary
The Board meeting also approved the audited Standalone and Consolidated Financial Statements for the quarter and financial year ended March 31, 2026.A summary of the core financial reporting for the year ended March 31, 2026, is provided below:
| Financial Metric | Standalone (Rs. in Lakhs) | Consolidated (Rs. in Lakhs) |
|---|---|---|
| Total Income | 47,163.00 | 170,269.01 |
| Total Expenditure | 44,400.41 | 161,452.18 |
| Net Profit (Period) | 2,012.32 | 6,605.75 |
| Total Comprehensive Income | 2,617.25 | 7,211.42 |
| Basic & Diluted EPS (Rs.) | 0.37 | 1.21 |
The Board of Directors, through the Audit Committee, recommended the audit re-appointment of M/s. Vijender Sharma & Co. for the financial year 2026-2027.
MOREPENLAB Stock Price Movement
Morepen Laboratories Limited shares closed today, rallying 1.10% to settle at ₹43.92. The stock saw significant activity, trading on a substantial volume of 4.55 million shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: